1. ZHAW digitalcollection
  2. School of Engineering
  3. Publikationen
  4. Publikationen School of Engineering
Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: https://doi.org/10.21256/zhaw-25991
Langanzeige der Metadaten
DC ElementWertSprache
dc.contributor.authorRiesterer, Oliver-
dc.contributor.authorAdemaj, Adela-
dc.contributor.authorPuric, Emsad-
dc.contributor.authorEberle, Brigitte-
dc.contributor.authorBeck, Marcus-
dc.contributor.authorGomez, Silvia-
dc.contributor.authorMarder, Dietmar-
dc.contributor.authorOberacker, Eva-
dc.contributor.authorRogers, Susanne-
dc.contributor.authorHälg, Roger A.-
dc.contributor.authorKern, Thomas-
dc.contributor.authorSchwenne, Sonja-
dc.contributor.authorStein, Jürgen-
dc.contributor.authorStutz, Emanuel-
dc.contributor.authorTimm, Olaf-
dc.contributor.authorZschaeck, Sebastian-
dc.contributor.authorWeyland, Mathias S.-
dc.contributor.authorVeltsista, Paraskevi D.-
dc.contributor.authorWyler, Stephen-
dc.contributor.authorWust, Peter-
dc.contributor.authorScheidegger, Stephan-
dc.contributor.authorBodis, Stephan-
dc.contributor.authorGhadjar, Pirus-
dc.date.accessioned2022-11-11T09:42:48Z-
dc.date.available2022-11-11T09:42:48Z-
dc.date.issued2022-
dc.identifier.issn0265-6736de_CH
dc.identifier.issn1464-5157de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/25991-
dc.description.abstractBackground: Transurethral resection of bladder tumor (TUR-BT) followed by chemoradiation (CRT) is a valid treatment option for patients with muscle-invasive bladder cancer (MIBC). This study aimed to investigate the efficacy of a tetramodal approach with additional regional hyperthermia (RHT). Methods: Patients with stages T2–4 MIBC were recruited at two institutions. Treatment consisted of TURBT followed by radiotherapy at doses of 57–58.2 Gy with concurrent weekly platinum-based chemotherapy and weekly deep RHT (41–43 C, 60 min) within two hours of radiotherapy. The primary endpoint was a complete response six weeks after the end of treatment. Further endpoints were cystectomy-free rate, progression-free survival (PFS), local recurrence-free survival (LRFS), overall survival (OS) and toxicity. Quality of life (QoL) was assessed at follow-up using the EORTC-QLQ-C30 and QLQ-BM30 questionnaires. Due to slow accrual, an interim analysis was performed after the first stage of the two-stage design. Results: Altogether 27 patients were included in the first stage, of these 21 patients with a median age of 73 years were assessable. The complete response rate of evaluable patients six weeks after therapy was 93%. The 2-year cystectomy-free rate, PFS, LRFS and OS rates were 95%, 76%, 81% and 86%, respectively. Tetramodal treatment was well tolerated with acute and late G3–4 toxicities of 10% and 13%, respectively, and a tendency to improve symptom-related quality of life (QoL) one year after therapy. Conclusion: Tetramodal therapy of T2–T4 MIBC is promising with excellent local response, moderate toxicity and good QoL. This study deserves continuation into the second stage.de_CH
dc.language.isoende_CH
dc.publisherTaylor & Francisde_CH
dc.relation.ispartofInternational Journal of Hyperthermiade_CH
dc.rightshttps://creativecommons.org/licenses/by/4.0/de_CH
dc.subjectBladder cancerde_CH
dc.subjectBladder preservationde_CH
dc.subjectRadiochemotherapyde_CH
dc.subjectRegional hyperthermiade_CH
dc.subjectTetramodal therapyde_CH
dc.subjectAgedde_CH
dc.subjectCombined modality therapyde_CH
dc.subjectHumande_CH
dc.subjectMusclede_CH
dc.subjectQuality of lifede_CH
dc.subjectHyperthermia, inducedde_CH
dc.subjectUrinary bladder neoplasmde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleTetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB studyde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Engineeringde_CH
zhaw.organisationalunitInstitut für Angewandte Mathematik und Physik (IAMP)de_CH
dc.identifier.doi10.1080/02656736.2022.2109763de_CH
dc.identifier.doi10.21256/zhaw-25991-
dc.identifier.pmid35993234de_CH
zhaw.funding.euNode_CH
zhaw.issue1de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end1087de_CH
zhaw.pages.start1078de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume39de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Enthalten in den Sammlungen:Publikationen School of Engineering

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
2022_Riesterer-etal_Tetramodal-therapy-with-transurethral-resection-bladder-cancer.pdf1.56 MBAdobe PDFMiniaturbild
Öffnen/Anzeigen
Zur Kurzanzeige
Riesterer, O., Ademaj, A., Puric, E., Eberle, B., Beck, M., Gomez, S., Marder, D., Oberacker, E., Rogers, S., Hälg, R. A., Kern, T., Schwenne, S., Stein, J., Stutz, E., Timm, O., Zschaeck, S., Weyland, M. S., Veltsista, P. D., Wyler, S., et al. (2022). Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study. International Journal of Hyperthermia, 39(1), 1078–1087. https://doi.org/10.1080/02656736.2022.2109763
Riesterer, O. et al. (2022) ‘Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study’, International Journal of Hyperthermia, 39(1), pp. 1078–1087. Available at: https://doi.org/10.1080/02656736.2022.2109763.
O. Riesterer et al., “Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study,” International Journal of Hyperthermia, vol. 39, no. 1, pp. 1078–1087, 2022, doi: 10.1080/02656736.2022.2109763.
RIESTERER, Oliver, Adela ADEMAJ, Emsad PURIC, Brigitte EBERLE, Marcus BECK, Silvia GOMEZ, Dietmar MARDER, Eva OBERACKER, Susanne ROGERS, Roger A. HÄLG, Thomas KERN, Sonja SCHWENNE, Jürgen STEIN, Emanuel STUTZ, Olaf TIMM, Sebastian ZSCHAECK, Mathias S. WEYLAND, Paraskevi D. VELTSISTA, Stephen WYLER, Peter WUST, Stephan SCHEIDEGGER, Stephan BODIS und Pirus GHADJAR, 2022. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer : early results of a multicenter phase IIB study. International Journal of Hyperthermia. 2022. Bd. 39, Nr. 1, S. 1078–1087. DOI 10.1080/02656736.2022.2109763
Riesterer, Oliver, Adela Ademaj, Emsad Puric, Brigitte Eberle, Marcus Beck, Silvia Gomez, Dietmar Marder, et al. 2022. “Tetramodal Therapy with Transurethral Resection Followed by Chemoradiation in Combination with Hyperthermia for Muscle-Invasive Bladder Cancer : Early Results of a Multicenter Phase IIB Study.” International Journal of Hyperthermia 39 (1): 1078–87. https://doi.org/10.1080/02656736.2022.2109763.
Riesterer, Oliver, et al. “Tetramodal Therapy with Transurethral Resection Followed by Chemoradiation in Combination with Hyperthermia for Muscle-Invasive Bladder Cancer : Early Results of a Multicenter Phase IIB Study.” International Journal of Hyperthermia, vol. 39, no. 1, 2022, pp. 1078–87, https://doi.org/10.1080/02656736.2022.2109763.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.